|
Match
|
Document |
Document Title |
|
|
7439224 |
Indications of mannan-binding lectin (MBL) in the treatment of immuno-compromised individuals
The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least...
|
|
|
7439418 |
Anti-microbial peptide known as halocyntin, gene coding for said peptide, vector, transformed organism and composition containing said peptide
An isolated peptide having an amino acid sequence FWGHIWNAVKRVGANALHGAVTGALS (SEQ ID No. 1), its derivatives and its fragments containing at least 7 amino acids.
|
|
|
7439234 |
Method for treating cancer patients undergoing chemotherapy
A method for treating cancer patients undergoing chemotherapeutic treatments by administering Product R, a peptide-nucleic acid preparation, is disclosed.
|
|
|
7439221 |
Methods and compositions for modulating gamete adhesion
Methods and compositions for modulating mammalian gamete adhesion are provided. Representative modulators of gamete adhesion include, but are not limited to polypeptides comprising at least one...
|
|
|
7435408 |
Porous particles comprising excipients for deep lung delivery
Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a...
|
|
|
7435419 |
Methods of diagnosing and treating pre-eclampsia or eclampsia
Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia by detecting the levels of placental growth factor in a subject.
|
|
|
7435716 |
Compounds pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia
Novel conjugates of bacterial outer membrane binding peptides, preferably having bacterial sensitization activity, and immune cells chemotactic peptides, and pharmaceutical compositions containing...
|
|
|
7435421 |
Derivatives of choline binding proteins for vaccines
The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of...
|
|
|
7435420 |
Dipeptidyl peptidase IV inhibitors for the treatment of anxiety
The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression,...
|
|
|
7435418 |
Receptor for B. anthracis toxin
The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the...
|
|
|
7435718 |
CXCR4 antagonist treatment of hematopoietic cells
In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication,...
|
|
|
7435717 |
Pharmaceutical formulations, methods, and dosing regimens for the treatment and prevention of acute coronary syndromes
The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I...
|
|
|
7432301 |
Use of S-nitrosothiol signaling to treat disordered control of breathing
The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem...
|
|
|
7431935 |
Proteins within the type E botulinum neurotoxin complex
The invention features a polypeptide complex synthesized by bacteria of the genus Clostridia that contains the serotype E botulinum neurotoxin and five neurotoxin associated polypeptides having...
|
|
|
7432239 |
Polyoxyalkylene compound and method for making
A process for forming a conjugate of a polyoxyalkylene polymer, such as polyethylene glycol, with a compound containing an amine group(s) and/or a sulfide group(s) by reacting the compound with an...
|
|
|
7431936 |
Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection
The present invention provides the RSP-1 and RSP-2 proteins which are involved in the cytoadhesion of P. falciparum during ring-stage infection of erythrocytes, antibodies which bind to the...
|
|
|
7432341 |
Cytokine receptor modulators and method of modulating cytokine receptor activity
The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate...
|
|
|
7432237 |
Methods of treating asthma by administering interleukin-17 receptor
Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
|
|
|
7432236 |
Vasostatin as marrow protectant
Specific fragments of vasostatin are disclosed. Also disclosed is a method of stimulating the proliferation or survival of a hematopoietic cell exposed to a chemotherapeutic agent or irradiation...
|
|
|
7432238 |
Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human...
|
|
|
7432251 |
Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R
This invention provides a method for regulating migration of neuronal progenitor cells in the nervous system of a mammal. The method comprises providing a mammal with TNR, a biologically active...
|
|
|
7432241 |
Device for treating diabetes and methods thereof
A composite supported vascular graft comprising Vascular Endothelial Growth Factor (VEGF) and/or Platelet Derived Growth Factor (PDGF) for enhanced site-specific angiogenesis and methods thereof...
|
|
|
7429563 |
Peptide carrier for drug delivery
The present invention is directed to compositions based on myeloperoxidase amino acid sequence which may be used as therapeutic agents or as delivery vehicles for the delivery of other therapeutic...
|
|
|
7429388 |
Vaccine for nontypeable Haemophilus influenzae infection
This invention provides a method for identifying strains of nontypeable Haemophilus influenzae that can be used as immunogenic compositions having specificity against a plurality of Haemophilus...
|
|
|
7429483 |
Use of nerve growth factor for the storage, culture or treatment of cornea
The nerve growth factor (NGF) is used for the storage of corneas in culture, for the production and the storage in vitro of single cell populations of the corneal morphological and functional unit...
|
|
|
7429561 |
Method for stimulating cell growth using sponge protein hydrolysates
A method for stimulating cell growth includes administrating to a candidate a sponge protein hydrolysate which is a product by acidic hydrolysis of sponge skeleton fibers (spongin fibers) obtained...
|
|
|
7429384 |
Chimeric antagonist anth1
A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit...
|
|
|
7429559 |
Controlled release composition and method of producing the same
A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of...
|
|
|
7429560 |
Ketoamide inhibitors in chronic nerve disease
Compositions and methods for treating neural pathologies are provided. In particular, compositions and methods for treating neural pathologies including axonal degeneration are provided. The...
|
|
|
7427590 |
Neurothrophic components of the ADNF I complex
This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases...
|
|
|
7427593 |
Methods of making triacylglycerol using phospholipid:Diacylglycerol acyltransferase
The present invention relates to the production of triacylglycerol in a transformed organism or host cell, by means of a nucleotide sequence from S. cerevisiae, whereby said enzyme catalyzes the...
|
|
|
7427403 |
Methods for inhibiting lymphotoxin β receptor signalling
This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents...
|
|
|
7427662 |
Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
Apolipoprotein A-I-rich Lhigh-density Lipoprotein 2 (HDL2) and Apolipoprotein A-I (ApoA-I) was discovered to inhibit angiogenesis in an in vitro human angiogenesis model, the human placental vein...
|
|
|
7427607 |
Drug administration method
A method of administering a drug whereby a fine drug powder can be accurately administered to a target site (in particular, a target site in the body cavity) via fluidization and spraying with a...
|
|
|
7427597 |
Method of treating brain tissue damages
A method of treating brain tissue damage, including administering to a subject in need thereof an effective amount of secretoneurin. Disclosed are methods of promoting angiogenesis or neurogenesis...
|
|
|
7427589 |
Use of cytokine inhibitors
The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a...
|
|
|
7427602 |
Sustained DNA delivery from structural matrices
Disclosed are particular 3-dimensional structural matrices containing nucleic acids, various fabrication processes and methods for the prolonged release of nucleic acids in various biological...
|
|
|
7427404 |
Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the aminoacid residues Glu129, Asp11, Trp26,...
|
|
|
7427408 |
Quorum sensing and biofilm formation
The present invention is based on the discovery that interspecies quorum sensing is related to biofilm formation. The present invention provides methods useful for treating or preventing biofilm...
|
|
|
7427503 |
Method for transferring material in a cell system
Described is a method for method for transferring material through the membrane of at least one cell, wherein the transfer is carried out in the presence of trehalose. This method is applicable in...
|
|
|
7425535 |
Therapeutic pore-forming peptides
A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by...
|
|
|
7425217 |
System and method for inhibiting cellular proliferation with tachykinins
Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in...
|
|
|
7425533 |
Modified hirudin proteins and T-cell epitopes in hirudin
Modified forms of hirudin having improved properties are disclosed. The modified hirudin compounds are hirudin variants comprising amino acid substitutions in the sequence of hirudin. Peptide...
|
|
|
7425339 |
CD8alpha mutants
The present invention provides modified CD8 molecules whose binding to MHC is enhanced compared to wild-type CD8, wherein Ser 53 of at least one CD8α chain thereof is mutated to another amino...
|
|
|
7425540 |
Method for modification of NMDA receptors through inhibition of Src
The present invention provides a method for modifying the activity of NMDA (N-methyl-D-aspartate)receptors in cells by inhibition of the interaction of the unique domain of the tyrosine kinase Src...
|
|
|
7425605 |
PRO1486 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7425534 |
Compositions and methods for modulating muscle cell and tissue contractility
The present invention relates to compositions and methods comprising one or more domains of urokinase-type plasminogen activator (uPA) in an amount effective to modulate one or more of the...
|
|
|
7425549 |
Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
A bisphosphonate for the treatment of osteonecrosis and/or osteonecrosis dissecans. The drug may further be used to prevent the onset of osteonecrosis and/or osteonecrosis dissecans and any...
|
|
|
7425539 |
Factor IXa for the treatment of bleeding disorders
The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating...
|
|
|
7425338 |
Clostridial toxin derivatives and methods for treating pain
Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a...
|